Compare EXPO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | ZLAB |
|---|---|---|
| Founded | 1967 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1996 | 2017 |
| Metric | EXPO | ZLAB |
|---|---|---|
| Price | $88.48 | $22.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $90.67 | $34.21 |
| AVG Volume (30 Days) | 382.2K | ★ 1.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $582,014,000.00 | $460,156,000.00 |
| Revenue This Year | $14.34 | N/A |
| Revenue Next Year | $8.95 | $22.47 |
| P/E Ratio | $48.51 | ★ N/A |
| Revenue Growth | 4.21 | ★ 15.33 |
| 52 Week Low | $51.91 | $15.96 |
| 52 Week High | $90.51 | $29.02 |
| Indicator | EXPO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 73.22 | 40.01 |
| Support Level | $64.40 | $21.71 |
| Resistance Level | $90.51 | $26.64 |
| Average True Range (ATR) | 2.56 | 1.34 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 81.08 | 7.53 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.